Business Wire

DEEPTECH-LABS

Share
Europe’s Only Deeptech Demo Day: Deeptech Labs’ Unveil 6 New Accelerator Start-ups

Deeptech Labs , the accelerator and VC fund for post-Seed, pre-Series A deeptech companies will unveil its Spring cohort of 6 deeptech start-ups to an online audience of investors on 21st June. More than 120 VCs and Corporate Entities have previously attended its virtual demo days, demonstrating the significant and growing interest in the European deeptech sector.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220614005112/en/

Deeptech Labs is a Cambridge-based accelerator programme and VC fund, founded in 2020 by ARM, Cambridge Innovation Capital, Martlet Capital, Ewan Kirk and the University of Cambridge. The accelerator supports deeptech entrepreneurs as they move from prototype and proof of concept to scalable products and services, and connects them to Deeptech Labs’ extensive network of deeptech investors.

The Deeptech Labs accelerator programme and investment fund was founded to fill a significant gap in the European venture market and accelerate the growth of promising early-stage deeptech companies. Deeptech Labs supports its cohort companies through a specially-designed thirteen week accelerator programme, connecting founders with a global network of more than 50 world-leading deeptech entrepreneurs, technology experts and investors.

Watch Demo Day elevator pitches from the Spring ’22 cohort:

Anaphite (Bristol, UK) incorporates graphene into battery materials, to enable the creation of super-fast charge, long-range batteries - something that will have significant impact on the EV market.

  • Watch Anaphite’s 3-minute elevator pitch here

Toposens (Munich, Germany) is the world’s only 3D ultrasonic sensing technology for advanced collision avoidance. It uses echolocation and signal processing algorithms to make autonomous vehicles in the robotics and automotive industry smarter and safer.

  • Watch Toposens’ 3-minute elevator pitch here

SonicEdge (Shoham, Israel) has developed the world’s smallest speaker-in-chip that uses breakthrough ultrasound technology to completely transform the audio experience.

  • Watch SonicEdge’s 3-minute elevator pitch here

iKVA (Cambridge, UK) is an early-stage AI Knowledge Management company creating solutions for organisations to discover data and intelligently and proactively provide it to users when they need it, enabling better business insights.

  • Watch iKVA’s 3-minute elevator pitch here

Inovo Robotics (Guildford, UK) are democratising robotics with modular, no-code, low cost “cobots” that open up completely new opportunities for safe, flexible automation.

  • Watch Inovo Robotics’ 3-minute elevator pitch here

Nestwave (Paris, France) Nestwave provides advanced, IoT geolocation solutions to IoT modem and DSP vendors to significantly improve localization accuracy in critical indoor and dense urban environments while greatly reducing power consumption and solution footprint.

  • Watch Nestwave’s 3-minute elevator pitch here

Miles Kirby, CEO Deeptech Labs said, “Europe has a number of global advantages in deeptech – we have 50% of the world’s best universities and the highest number of highly cited research papers - but there’s a disparity when it comes to European investment in deeptech companies. European deeptech companies attract $33 billion compared to $144 billion in the US .

Thanks to our deeptech-specific accelerator programme, our cohort companies are stronger, more resilient and have highly focused go-to-market strategies and that’s why so many investors attend our Demo Days – and how we are helping to fix the European deeptech investment gap.”

  • Watch Miles’ 5 minute introduction to Deeptech Labs here .

Editors Notes

Deeptech Labs is an accelerator, VC fund, and the catalyst for deeptech success. Twice a year, its cohort of start-ups are embedded in a powerful network of successful entrepreneurs, expert practitioners, leading researchers, and deeptech organisations worldwide. Deeptech Labs is founded by ARM, Cambridge Innovation Capital, Martlet Capital, Ewan Kirk and the University of Cambridge - forefront institutions and individuals at the heart of the Cambridge and global technology ecosystems.

The company is headquartered in Cambridge, UK.

For more information, please visit dtl.vc

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release

Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release

The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release

Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye